Radioactivity

Adamis Announces Agreement to Sell Portion of US Compounding Business

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Natural sciences, Physical sciences, Radiation therapy, Radioactivity, Radiobiology, Pharmaceutical industry, Dermatitis, Medication

The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.

Key Points: 
  • The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.
  • Adamis expects to use the proceeds from the sale for general corporate purposes and to fund ongoing development of its pipeline.
  • Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, and radiation dermatitis.
  • Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis filings from time to time with theU.S.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021
Radiobiology, Physical sciences, Radiation, Ionizing radiation, Radioactivity, Radiation protection, Medical physics, Nuclear physics, Fluoroscopy, Interventional cardiology, Lead shielding, StemRad

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021
Radiobiology, Physical sciences, Radiation, Ionizing radiation, Radioactivity, Radiation protection, Medical physics, Nuclear physics, Fluoroscopy, Interventional cardiology, Lead shielding, StemRad

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

David K. Roemer, PhD, Celebrated for Excellence in Education and Theology

Retrieved on: 
Monday, July 26, 2021
Manufacturing, Companies, Industry economics), Radioactivity, Radiobiology, Medical physics, Auschwitz concentration camp, Siemens, Toshiba, Radiation therapy, Therapy, Ionizing radiation

Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Key Points: 
  • Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
  • In 1972, he was recruited by Litton Medical Systems as a manager of radiation therapy products.
  • Throughout the following five years, he provided technical and sale support for radiation therapy equipment that had been manufactured by Toshiba Corporation.
  • While working for Siemens AG, he completed his education by earning a Master of Business Administration from Pace University's Lubin School of Business.

Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac

Retrieved on: 
Friday, July 23, 2021
Radiobiology, Medical physics, Radiation therapy, Radioactivity, Nuclear physics, Physical sciences, Natural sciences

ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 36 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system. The abstracts are being reported at the 63rd Annual Meeting & Exhibition of the American Association of Physicists in Medicine (AAPM), which is being held virtually July 25-29, 2021."The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta. "These abstracts also reflect the power of the Elekta MR-Linac Consortium,  which played a critical role in developing the technology behind  the first high-field MR-Linac,  to generate robust data that drives evidence-based clinical decision making. We continue to expand the Consortium to build the collection of data from around the world and make advanced radiation medicine available to all cancer patients, regardless of where they are treated."

Key Points: 
  • The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.
  • "The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta.
  • Mr. Brown highlighted several abstracts that exemplify the benefits that Elekta Unity can provide to patients and care centers.
  • This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity.

Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac

Retrieved on: 
Friday, July 23, 2021
Radiobiology, Medical physics, Radiation therapy, Radioactivity, Nuclear physics, Physical sciences, Natural sciences

The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.

Key Points: 
  • The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.
  • "The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta.
  • Mr. Brown highlighted several abstracts that exemplify the benefits that Elekta Unity can provide to patients and care centers.
  • This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity.

Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, July 22, 2021
Physical sciences, Natural sciences, Physics, Isotopes, Nuclear chemistry, Radioactivity, Radionuclide, Plus Therapeutics

); Conference ID: PSTVQ221

Key Points: 
  • ); Conference ID: PSTVQ221
    The webcast can be accessed live via the investor section of the Plus Therapeutics website at ir.plustherapeutics.com/events and will be available for replay beginning two hours after the conclusion of the conference call.
  • Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.
  • There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future.

DefenderShield Announces the Launch of Ultra Armor™ Technology, the Most Effective 5G and EMF Radiation Shielding Developed to Date

Retrieved on: 
Thursday, July 22, 2021
Telecommunications, Technology, Science and technology, Mobile telecommunications, Radiobiology, Electromagnetism, Ionizing radiation, Mutagens, Radioactivity, 5G, Radiation, Mobile phone

The extended use of mobile electronic devices and their close proximity to our bodies exposes us to increased levels of Electromagnetic Field (EMF) radiation.

Key Points: 
  • The extended use of mobile electronic devices and their close proximity to our bodies exposes us to increased levels of Electromagnetic Field (EMF) radiation.
  • In the industry, DefenderShield is known as the trusted expert in EMF shielding and education.
  • DefenderShield technology reduces your exposure to Electromagnetic Radiation (EMF) emitted by mobile devices like laptops, tablets, and cell phones.
  • Backed by scientific lab testing, DefenderShield technology blocks up to 99.99% of EMF radiation, including the entire 5G wireless network.

TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)

Retrieved on: 
Thursday, July 22, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Physical sciences, Natural sciences, Chemistry, Radiobiology, Medical physics, Radioactivity, Boron, Gadolinium, Neutron capture therapy of cancer, Radiation therapy, Neutron radiation, Neutron, Biologically Targeted Radiation Therapy (BNCT), TAE Life Sciences, BIOLOGICALLY TARGETED RADIATION THERAPY (BNCT), TAE LIFE SCIENCES

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221.
  • Most BNCT clinical studies to date have been carried out using boronophenylalanine (BPA) as the boron target drug.
  • When neutron radiation is applied, the boron atoms react to generate alpha particles that destroy cancer cells.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging

Retrieved on: 
Thursday, July 22, 2021
Radiobiology, Radiation therapy, Radioactivity, Lymph node, Physical sciences, Natural sciences, Medicine

SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced todaythat the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact System, the next-generation TomoTherapy platform, with ClearRT helical fan-beam kVCT imaging.

Key Points: 
  • SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced todaythat the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact System, the next-generation TomoTherapy platform, with ClearRT helical fan-beam kVCT imaging.
  • With the installation of ClearRT the team has raised the bar for other hospitals using radiation therapy as an option in cancer care.
  • The treatment region included the oral cavity and neck lymph nodes, so minimizing dose to nearby critical organs was crucial.
  • "The HKSH team is excited to expand on the Radixact System's capabilities with the addition of the ClearRT imaging technology.